Xponance Inc. Raises Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Xponance Inc. grew its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 4.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 9,786 shares of the medical equipment provider’s stock after buying an additional 427 shares during the period. Xponance Inc.’s holdings in Lantheus were worth $875,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of LNTH. Janus Henderson Group PLC increased its position in shares of Lantheus by 7.7% in the 3rd quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock valued at $393,844,000 after acquiring an additional 257,022 shares during the period. Geode Capital Management LLC grew its stake in Lantheus by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after purchasing an additional 32,551 shares during the last quarter. Reinhart Partners LLC. increased its holdings in shares of Lantheus by 9.9% in the fourth quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider’s stock valued at $122,280,000 after purchasing an additional 123,282 shares during the period. Swedbank AB raised its stake in shares of Lantheus by 53.3% in the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock worth $99,054,000 after purchasing an additional 385,000 shares during the last quarter. Finally, Portolan Capital Management LLC lifted its holdings in shares of Lantheus by 6.1% during the third quarter. Portolan Capital Management LLC now owns 670,881 shares of the medical equipment provider’s stock worth $73,629,000 after purchasing an additional 38,776 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Insider Buying and Selling at Lantheus

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the sale, the chief financial officer now owns 113,860 shares of the company’s stock, valued at approximately $11,445,207.20. The trade was a 8.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now owns 440,399 shares of the company’s stock, valued at $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 64,109 shares of company stock worth $6,110,806 in the last ninety days. 1.50% of the stock is owned by insiders.

Lantheus Stock Performance

NASDAQ:LNTH opened at $99.44 on Tuesday. The stock has a 50 day moving average price of $92.77 and a 200 day moving average price of $96.47. The stock has a market cap of $6.81 billion, a PE ratio of 16.55 and a beta of 0.38. Lantheus Holdings, Inc. has a one year low of $57.92 and a one year high of $126.89.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The company had revenue of $391.11 million for the quarter, compared to analysts’ expectations of $376.61 million. As a group, analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

LNTH has been the topic of several recent research reports. Truist Financial upped their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a report on Thursday, February 27th. JMP Securities reaffirmed a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. The Goldman Sachs Group assumed coverage on Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective for the company. Finally, B. Riley lowered their target price on Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research note on Friday. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Lantheus currently has an average rating of “Moderate Buy” and a consensus price target of $129.43.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.